资讯

MyChesCo on MSN15 小时
ENHERTU Shows Promise in Early-Stage HER2-Positive Breast Cancer
Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when ...
Fierce Biotech4 小时
Kinase inhibitor biotech Enliven calls time on ph. 1 HER2 solid tumor program
Enliven Therapeutics has decided against taking its phase 1-stage solid tumor drug into further development next year in ...
England’s drug approval body resists pharma pressure to loosen processes
England’s drug approval body has resisted pressure from pharmaceutical companies to loosen its process for recommending drugs and is pressing instead for the NHS to speed up the rollout of approved ...
pharmaphorum16 小时
AstraZeneca to work with Lilly on Alzheimer's drug
AstraZeneca has enlisted the help of Lilly in the development of its new Alzheimer's candidate AZD3293. The drug is an oral beta secretase cleaving enzyme (BACE) inhibitor, which the companies ...
pharmaphorum16 小时
Chord gets $16m to challenge Alexion with oral NMOSD drug
AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time. The importance of biosimilars only continues to ...